首页 | 本学科首页   官方微博 | 高级检索  
     


Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer
Authors:Filipa Lynce MD  Matthew J. Blackburn MD  Rebecca Zhuo MD  Christopher Gallagher MD  Olwen M. Hahn MD  Maysa Abu-Khalaf MD  Mahsa Mohebtash MD  Tianmin Wu MS  Paula R. Pohlmann MD  Asma Dilawari MD  Shruti R. Tiwari MD  Ami Chitalia MD  Robert Warren MD  Ming Tan PhD  Ayesha N. Shajahan-Haq PhD  Claudine Isaacs MD
Affiliation:1. Georgetown Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia;2. Georgetown University School of Medicine, Georgetown University, Washington, District of Columbia;3. Washington Cancer Institute, MedStar Washington Hospital Center, Washington, District of Columbia;4. Section of Hematology/Oncology, University of Chicago, Chicago, Illinois;5. Sidney Kimmel Cancer Center at Jefferson Health, Thomas Jefferson University, Philadelphia, Pennsylvania;6. MedStar Franklin Square Cancer Center, Baltimore, Maryland;7. Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, District of Columbia;8. Georgetown Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia

Washington Cancer Institute, MedStar Washington Hospital Center, Washington, District of Columbia;9. Georgetown University Medical Center and Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia

Abstract:
Keywords:African Americans  benign ethnic neutropenia  cyclin-dependent kinase 4/6 (CDK4/6) inhibitor  Duffy antigen receptor for chemokines (DARC)  Duffy null  endocrine therapy  neutropenia  palbociclib  safety
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号